What question did this study set out to answer?

This study aims to evaluate real-world outcomes in advanced NSCLC patients with common EGFR mutations over time.

February 22, 2026Open Access

FIN-EGFRprint: a Finnish real-word study on treatments and outcomes in advanced NSCLC with common EGFR mutations

Puntos clave

This study aims to evaluate real-world outcomes in advanced NSCLC patients with common EGFR mutations over time.
Retrospective observational study
Analyzed patients with EGFR mutations from 2010 to 2023
Utilized Kaplan–Meier survival and multivariable Cox regression analyses
Stratified patients by cohorts based on diagnosis date and available TKIs
Chemotherapy use as first-line therapy decreased from 32% to 6% from 2010-2016 to 2020-2023
Median time to next treatment improved from 9.7 to 21.6 months over the same period
Median overall survival increased from 19.1 months to 29.3 months
Significant improvements were noted for both TTNT and OS in 2020-2023 versus earlier periods

Resumen

Background and purpose: The treatment of advanced non-small cell lung cancer (aNSCLC) with common epidermal growth factor receptor (cEGFR) mutations has evolved substantially over the last 15 years, with the discovery of activating epidermal growth factor receptor (EGFR) mutations and introduction of first-, second- and third generation (gen) EGFR tyrosine kinase inhibitors (TKIs) as first-line therapy. This retrospective observational study aimed to evaluate whether the introduction of these treatments has led to improved ‘real-world’ outcomes over time by analysing time to next treatment (TTNT) and overall survival (OS). Patient/material and methods: Patients (n = 379) with EGFR exon 19 deletion (Del19) or exon 21 L858R (L858R) substitution and aNSCLC were identified from two Finnish university hospital data lakes between 2010 and 2023. TTNT and OS were analysed from first-line treatment initiation using Kaplan–Meier survival and multivariable Cox regression analyses. Patients were stratified into three cohorts based on date of diagnosis and which TKIs were available at that time (1st-gen: 2010–2016, 2nd-gen: 2017–2020 and 3rd-gen: 2020–2023). Results: The use of chemotherapy as first-line therapy declined from 32% (2010–2016) to 6% (2020–2023), while 80% of patients received 3rd-gen TKIs as first-line treatment in 2020–2023. Median TTNT improved over time (9.7 to 13.2 to 21.6), with a significant improvement in 2020–2023 versus 2010–2016 (HR: 0.46; 95% CI: 0.33–0.64; p < 0.001). Median OS also increased over time (19.1 to 23.9 to 29.3 months) and was significantly higher in 2020–2023 versus 2010–2016 (HR: 0.56; 95% CI: 0.39–0.82; p = 0.002). Interpretation: ‘Real-world’ treatment outcomes for aNSCLC with cEGFR mutations have improved over time likely due to the transition from 1st- to 3rd-gen TKIs. However, real-word survival with TKIs remains lower than clinical trials results emphasizing the unmet need.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo